Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Shares Drop Again

Shares in Sequenom sank by double digits for the second week in a row to lead all decliners in the BCW Index for the week ended Tuesday. Sequenom dropped 12.08 percent for the week, following a drop of 13.24 percent the week before. Though the firm has not revealed any bad news recently, Lehman Brothers dumped 1 million shares of Sequenom stock last week at a price of $4.55 per share.
 
Beckman Coulter led all gainers for the week with a 6.62 percent rise, followed by Illumina, which closed up 5.67 percent.
 
Overall, the BCW Index rose .72 percent for the tracking period, beating the Dow Jones Industrial Average, which fell .4 percent; the Nasdaq, which dropped 2.7 percent; and the Nasdaq Biotech Index, which fell 1 percent.

 
BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Closing Price (Jan. 23, 2007)
Starting Price Jan. (Jan. 16, 2007)
% change
Affymetrix
AFFX
24.7
25.41
-2.79
Agilent
A
32.71
33.54
-2.47
Applied Biosystems
ABI
36.06
36.33
-0.74
Beckman
BEC
63.9
59.93
6.62
Becton Dickinson
BDX
73.91
72.54
1.89
Bio-Rad
BIO
82.83
83.34
-0.61
Bruker
BRKR
7.51
7.46
0.67
Caliper
CALP
5.49
5.66
-3.00
Cepheid
CPHD
8.25
8.48
-2.71
Illumina
ILMN
40.98
38.78
5.67
Invitrogen
IVGN
59.83
58.81
1.73
Luminex
LMNX
13.01
13.11
-0.76
Millipore
MIL
68.97
66.67
3.45
Molecular Devices
MDCC
23.02
23.88
-3.60
PerkinElmer
PKI
22.35
22.66
-1.37
Qiagen
QGEN
16.1
16.52
-2.54
Sequenom
SQNM
4.15
4.72
-12.08
Sigma-Aldrich
SIAL
38.17
38.53
-0.93
Stratagene
STGN
7.07
7.18
-1.53
Thermo
TMO
48.02
48.04
-0.04
Third Wave
TWTI
4.94
5.0
-1.20
Waters
WAT
54.97
55.05
-0.15
BCW Index Average
33.50
33.26
0.72
The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.